SAN
FRANCISCO, Sept. 6, 2023 /PRNewswire/ -- Nektar
Therapeutics (Nasdaq: NKTR) today announced that it will host a
virtual investor and analyst event on Wednesday, September 13, 2023 at 11:00 a.m. EST / 8:00 a.m.
PST to discuss the final Phase 1b data of rezpegaldesleukin (REZPEG) in patients
with atopic dermatitis, the atopic dermatitis treatment landscape,
and the potential role of REZPEG, Nektar's novel, first-in-class
selective regulatory T-cell (Treg) therapy, in the treatment of
atopic dermatitis.
Nektar's Chief Research & Development Officer, Jonathan Zalevsky, Ph.D., will be presenting the
final Phase 1b data and
unveiling the trial design for the Phase 2b study of REZPEG in patients with moderate
to severe atopic dermatitis. He will be joined by Nektar's Chief
Medical Officer, Mary Tagliaferri,
M.D., and by leading dermatology experts, including:
- Dr. Jonathan Silverberg,
Professor of Dermatology at The George
Washington University School of Medicine and Health Sciences
and Director of Clinical Research and Contact Dermatitis;
- Dr. David Rosmarin, Chair of the
Department of Dermatology at Indiana
University and Kampen-Norins Scholar in Dermatology;
and,
- Dr. Raj Chovatiya, Assistant Professor of Dermatology at the
Northwestern University Feinberg School
of Medicine.
To access the conference call, please pre-register at Nektar
Earnings Call Registration. All registrants will receive dial-in
information and a PIN allowing them to access the live call.
Investors and analysts can also view slides and listen to the
live audio webcast of the presentation here. The event will also be
available for replay through October 13,
2023 on Nektar's website: www.nektar.com.
About the Presenters
Dr. Jonathan
Silverberg
Dr. Silverberg is Professor of Dermatology at The George Washington University School of Medicine and Health
Sciences in Washington, DC.
He is the Director of Clinical Research and Contact Dermatitis. Dr.
Silverberg's area of clinical subspecialty is inflammatory skin
disease, particularly atopic and contact dermatitis. Dr. Silverberg
has also been a local, national and/or international principal
investigator for numerous clinical trials for novel treatments in
atopic dermatitis and other inflammatory disorders. Dr.
Silverberg's research interests include drug development, clinical
trial design, biomarkers, dermato-epidemiology, health services
research, patient-reported outcomes, comorbidities and burden of
itch and inflammatory skin disease and evidence-based dermatology.
His publications include more than 1000 peer-reviewed articles,
abstracts and book chapters. He is an associate editor for the
Journal of the American Academy of Dermatology, British Journal of
Dermatology and Current Dermatology Reports.
Dr. David Rosmarin
Dr. Rosmarin is Chair of the Department of Dermatology at
Indiana University and is Kampen-Norins
Scholar in Dermatology. He is nationally recognized and serves as a
referral for physicians with difficult-to-manage inflammatory
diseases such as atopic dermatitis. Previously, Dr. Rosmarin served
as the Director of the Clinical Trials Unit in the Department of
Dermatology at Tufts Medical Center. His research interests focus
on development of novel therapeutics and investigating novel uses
of established therapies, with a particular focus on chronic skin
diseases such as atopic dermatitis, vitiligo, discoid lupus,
and hidradenitis suppuritiva. For his training, Dr. Rosmarin went
to medical school at NYU, dermatology
residency at Boston University-Tufts
combined training program, and fellowship at Brigham and Women's
Hospital.
Dr. Raj Chovatiya
Raj Chovatiya, M.D., Ph.D., MSCI is a board certified
dermatologist from Chicago,
Illinois with a clinical and research focus that includes
the intersection of cutaneous immunology and inflammatory disease.
He received his MD and PhD in immunology from Yale and completed his residency, postdoctoral
research fellowship, and MS in clinical investigation at
Northwestern University where he also
served as Chief Resident. Dr. Chovatiya has a particular interest
in optimizing patient-centered care, understanding chronic disease
burden especially in understudied inflammatory diseases, and
improving care across diverse skin types. He has published numerous
abstracts and manuscripts and has been nationally and
internationally recognized for his contributions as a clinician,
educator, researcher, and leader.
About Nektar Therapeutics
Nektar Therapeutics is a biopharmaceutical company with a
robust, wholly owned R&D pipeline of investigational medicines
in oncology and immunology as well as a portfolio of approved
partnered medicines. Nektar is headquartered in San Francisco, California, with additional
operations in Huntsville, Alabama.
Further information about the company and its drug development
programs and capabilities may be found online at
http://www.nektar.com.
Nektar Cautionary Note Regarding Forward-Looking
Statements
This press release contains forward-looking statements which can
be identified by words such as: "will," "may," "develop,"
"potential" and similar references to future periods. Examples of
forward-looking statements include, among others, statements
regarding the therapeutic potential of, and future development
plans for, rezpegaldesleukin. Forward-looking statements are
neither historical facts nor assurances of future performance.
Instead, they are based only on our current beliefs, expectations
and assumptions regarding the future of our business, future plans
and strategies, anticipated events and trends, the economy and
other future conditions. Because forward-looking statements relate
to the future, they are subject to inherent uncertainties, risks
and changes in circumstances that are difficult to predict and many
of which are outside of our control. Our actual results may differ
materially from those indicated in the forward-looking statements.
Therefore, you should not rely on any of these forward-looking
statements. Important factors that could cause our actual results
to differ materially from those indicated in the forward-looking
statements include, among others: (i) our statements regarding the
therapeutic potential of rezpegaldesleukin are based on preclinical
and clinical findings and observations and are subject to change as
research and development continue; (ii) rezpegaldesleukin is an
investigational agent and continued research and development for
this drug candidate is subject to substantial risks, including
negative safety and efficacy findings in future clinical studies
(notwithstanding positive findings in earlier preclinical and
clinical studies); (iii) rezpegaldesleukin is in clinical
development and the risk of failure is high and can unexpectedly
occur at any stage prior to regulatory approval; (iv) the
timing of the commencement or end of clinical trials and the
availability of clinical data may be delayed or unsuccessful due to
challenges caused by the COVID-19 pandemic, regulatory delays,
slower than anticipated patient enrollment, manufacturing
challenges, changing standards of care, evolving regulatory
requirements, clinical trial design, clinical outcomes, competitive
factors, or delay or failure in ultimately obtaining regulatory
approval in one or more important markets; (v) we may not achieve
the expected cost savings we expect from our 2022 corporate
restructuring and reorganization plan or our 2023 cost
restructuring plan and we may undertake additional restructuring
and cost-saving activities in the future, (vi) patents may not
issue from our patent applications for our drug candidates, patents
that have issued may not be enforceable, or additional intellectual
property licenses from third parties may be required; and (vii)
certain other important risks and uncertainties set forth in our
Annual Report on Form 10-Q filed with the Securities and Exchange
Commission on August 9, 2023. Any
forward-looking statement made by us in this press release is based
only on information currently available to us and speaks only as of
the date on which it is made. We undertake no obligation to update
any forward-looking statement, whether written or oral, that may be
made from time to time, whether as a result of new information,
future developments or otherwise.
Contact:
For Investors:
Vivian
Wu of Nektar Therapeutics
628-895-0661
For Media:
David Rosen
of Argot Partners
(212) 600-1902
david.rosen@argotpartners.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/nektar-therapeutics-to-host-virtual-investor--analyst-event-with-dermatology-experts-on-september-13th-301919902.html
SOURCE Nektar Therapeutics